Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

Abstract

Targeted therapy with BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) provides rapid disease control with high response rates in patients with BRAF-mutant metastatic melanoma. However, the majority of patients develop resistance to therapy during the course of therapy. Immune checkpoint inhibitors show a slower onset of action with lower response rates, with responders showing sustained response. The combination of BRAFi/MEKi and immune checkpoint inhibitors combines the hope for a fast, reliable and lasting response to therapy. Preclinical data supports this hypothesis. With the help of the PubMed database, a comprehensive search and analysis of preclinical and clinical studies on the combination of BRAFi/MEKi with immune checkpoint inhibitors was performed and yielded the following results: 1) In vivo, BRAFi and MEKi have no negative effects on immune cells; BRAFi and MEKi generate 2) an immune stimulating tumor microenvironment, 3) an increased infiltration of immune cells into the tumors, 4) a better recognition of melanoma cells by immune effector cells, and 5) a better functionality of the immune effector cells. In addition, in vivo experiments 6) demonstrated a superiority of the combination treatment compared to the individual strategies in both BRAF-mutant and BRAF wild-type melanomas. In summary, available data show that both BRAFi and MEKi have beneficial effects on the antitumor immunity and the tumor microenvironment as a whole, which is mediated by different mechanisms. Currently, clinical studies are underway to investigate combinations of BRAFi and MEKi with immune checkpoint inhibitors. The results of these studies are eagerly awaited.

Details

Original languageEnglish
Pages (from-to)151-159
Number of pages9
JournalPharmacological research
Volume136
Publication statusPublished - Oct 2018
Peer-reviewedYes

External IDs

PubMed 30145328
ORCID /0000-0003-4340-0402/work/145223814
ORCID /0000-0003-4340-9706/work/145224726

Keywords

ASJC Scopus subject areas

Keywords

  • Binimetinib (PubChem CID: 10288191), BRAF, Cobimetinib (PubChem CID: 16222096), Dabrafenib (PubChem CID: 44462760), Encorafenib (PubChem CID: 50922675), Immunological effects, Immunotherapy, MEK, Melanoma, Targeted therapy, Trametinib (PubChem CID: 11707110), Vemurafenib (PubChem CID: 42611257)